140 related articles for article (PubMed ID: 27177670)
21. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.
Somanchi SS; Lee DA
Methods Mol Biol; 2016; 1441():175-93. PubMed ID: 27177666
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
23. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
25. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
26. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
27. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
28. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
[TBL] [Abstract][Full Text] [Related]
29. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells.
Douka S; Brandenburg LE; Casadidio C; Walther J; Garcia BBM; Spanholtz J; Raimo M; Hennink WE; Mastrobattista E; Caiazzo M
J Control Release; 2023 Sep; 361():455-469. PubMed ID: 37567506
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive In Vivo Fluorescence Imaging of NK Cells in Preclinical Models of Adoptive Immunotherapy.
Somanchi SS
Methods Mol Biol; 2016; 1441():307-16. PubMed ID: 27177677
[TBL] [Abstract][Full Text] [Related]
31. Genetic modification of natural killer cells for adoptive cellular immunotherapy.
Pegram HJ; Kershaw MH; Darcy PK
Immunotherapy; 2009 Jul; 1(4):623-30. PubMed ID: 20635990
[TBL] [Abstract][Full Text] [Related]
32. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.
Boissel L; Betancur M; Lu W; Wels WS; Marino T; Van Etten RA; Klingemann H
Leuk Lymphoma; 2012 May; 53(5):958-65. PubMed ID: 22023526
[TBL] [Abstract][Full Text] [Related]
33. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors.
Tomaipitinca L; Russo E; Bernardini G
Mol Aspects Med; 2021 Aug; 80():100968. PubMed ID: 34045078
[TBL] [Abstract][Full Text] [Related]
34. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
35. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
[TBL] [Abstract][Full Text] [Related]
36. Natural killer cell homing and trafficking in tissues and tumors: from biology to application.
Ran GH; Lin YQ; Tian L; Zhang T; Yan DM; Yu JH; Deng YC
Signal Transduct Target Ther; 2022 Jun; 7(1):205. PubMed ID: 35768424
[TBL] [Abstract][Full Text] [Related]
37. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
38. 3D Nanochannel Electroporation for Macromolecular Nucleotide Delivery.
Chang L; Chitrakar C; Nouri M
Methods Mol Biol; 2020; 2050():69-77. PubMed ID: 31468480
[TBL] [Abstract][Full Text] [Related]
39. Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.
Carlsten M; Levy E; Karambelkar A; Li L; Reger R; Berg M; Peshwa MV; Childs RW
Front Immunol; 2016; 7():105. PubMed ID: 27047492
[TBL] [Abstract][Full Text] [Related]
40. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
